Gamida Cell appoints Board member Shawn Tomasello as new Chair of the Board of Directors

– USA, MA –  Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the election of current Board member Shawn Tomasello as Chair of the Board of Directors, effective immediately, succeeding Robert Blum who resigned from the Board.

“Shawn is a highly respected and seasoned biotech executive with tremendous experience in all dimensions of our industry, including corporate strategy and commercialization of innovative hematology, oncology, and cell therapies. We look forward to her leadership as we approach our May 1 FDA target action date for omidubicel and, if approved, shift our focus to commercialization,” said CEO, Abbey Jenkins.

The company also announced the resignations of Dr. Anat Cohen-Dayag and Dr. Naama Halevi-Davidov from the Board.

About Shawn Cline Tomasello

Shawn Tomasello joined Gamida Cell’s Board of Directors in June 2019, bringing extensive experience in leading successful commercial activities at several pharmaceutical companies and providing key strategic guidance on company boards. Most recently, she served as CCO of Kite Pharma, now part of Gilead Sciences, where she oversaw the global commercialization of Yescarta®, the first approved CAR-T therapy for non-Hodgkin lymphoma, and was a key executive in the Kite/Gilead acquisition for $11.9 billion in August 2017. Before joining Kite, Ms. Tomasello was CCO and had responsibility for medical affairs at Pharmacyclics. While at Pharmacyclics, the company’s market cap increased from $8 billion to $19 billion, and it was ultimately acquired by AbbVie for $21 billion. Ms. Tomasello has extensive strategic experience in building world-class organizations working across all relevant encompassing functions.

“I’m excited to take on the role of Chairwoman,” said Shawn Tomasello. “Gamida Cell is at an inflection point, with the potential FDA approval of omidubicel in the near term. This company has a therapy that can make a meaningful difference in the lives of patients, and an executive team that I’m confident can execute an effective launch.”

She holds a bachelor’s degree in marketing from the University of Cincinnati and an MBA from Murray State University and currently also serves on the public boards of AlloVir, TCR2 Therapeutics, Inc., and 4D Molecular Therapeutics.

About Gamida Cell

Gamida Cell is a cell therapy pioneer working to turn cells into powerful therapeutics. The company has a diverse pipeline of potentially curative cell therapy candidates for patients with blood cancers and solid tumors. We apply a proprietary expansion platform leveraging the properties of NAM to cell sources including umbilical cord blood-derived cells and natural killer (NK) cells to create allogeneic cell therapy candidates with the potential to redefine standards of care. These include omidubicel, an advanced cell therapy candidate for allogeneic hematopoietic stem cell transplant that, if approved, has the potential to expand access and improve outcomes for patients with blood cancers, and a line of enhanced and engineered NK cells targeted at solid tumors and hematological malignancies.


- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.